ResearcherYonsei UniversityActive in the last 2 years
Jee Hoon Kim
Matched on ORCID iD 0009-0003-1323-7728; OpenAlex author ID A5112841864. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 16
2024: 1 paper · 2025: 1 paper · 2026: 1 paper
Papers 3
- FOLFIRINOX vs. gemcitabine/nab-paclitaxel for metastatic pancreatic cancer: A real-world study. Co-author DOI 10.1016/j.tranon.2026.103085↗
- Early prediction of liver metastasis in pancreatic cancer using routine clinical data: an externally validated machine learning model. Co-author DOI 10.1186/s12885-025-15285-4↗
- Long-Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/cam4.70363↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jung Hyun Jo · 3 shared papers, 2024–2026 · strength 0.65
- Paper FOLFIRINOX vs. gemcitabine/nab-paclitaxel for metastatic pancreatic cancer: A real-world study. DOI 10.1016/j.tranon.2026.103085↗
- Paper Early prediction of liver metastasis in pancreatic cancer using routine clinical data: an externally validated machine … DOI 10.1186/s12885-025-15285-4↗
- Paper Long-Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma. DOI 10.1002/cam4.70363↗
- Moon Jae Chung · 3 shared papers, 2024–2026 · strength 0.65
- Paper FOLFIRINOX vs. gemcitabine/nab-paclitaxel for metastatic pancreatic cancer: A real-world study. DOI 10.1016/j.tranon.2026.103085↗
- Paper Early prediction of liver metastasis in pancreatic cancer using routine clinical data: an externally validated machine … DOI 10.1186/s12885-025-15285-4↗
- Paper Long-Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma. DOI 10.1002/cam4.70363↗
- Jeong Youp Park · 3 shared papers, 2024–2026 · strength 0.65
- Paper FOLFIRINOX vs. gemcitabine/nab-paclitaxel for metastatic pancreatic cancer: A real-world study. DOI 10.1016/j.tranon.2026.103085↗
- Paper Early prediction of liver metastasis in pancreatic cancer using routine clinical data: an externally validated machine … DOI 10.1186/s12885-025-15285-4↗
- Paper Long-Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma. DOI 10.1002/cam4.70363↗
- Sung Ill Jang · 2 shared papers, 2025–2026 · strength 0.47
- Hee Seung Lee · 2 shared papers, 2024–2025 · strength 0.38
- Paper Early prediction of liver metastasis in pancreatic cancer using routine clinical data: an externally validated machine … DOI 10.1186/s12885-025-15285-4↗
- Paper Long-Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma. DOI 10.1002/cam4.70363↗
- Seungmin Bang · 2 shared papers, 2024–2025 · strength 0.38
- Paper Early prediction of liver metastasis in pancreatic cancer using routine clinical data: an externally validated machine … DOI 10.1186/s12885-025-15285-4↗
- Paper Long-Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma. DOI 10.1002/cam4.70363↗
- Kyung In Shin · 2 shared papers, 2024–2025 · strength 0.38
- Paper Early prediction of liver metastasis in pancreatic cancer using routine clinical data: an externally validated machine … DOI 10.1186/s12885-025-15285-4↗
- Paper Long-Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma. DOI 10.1002/cam4.70363↗
- Jiyoung Keum · 1 shared paper, 2025 · strength 0.20
- Jae Hee Cho · 1 shared paper, 2025 · strength 0.20
- Y.J. Ko · 1 shared paper, 2025 · strength 0.20
- Mi‐Suk Park · 1 shared paper, 2024 · strength 0.18
- Seung‐seob Kim · 1 shared paper, 2024 · strength 0.18
- Seung Woo Park · 1 shared paper, 2024 · strength 0.18
- Min Sung Yoon · 1 shared paper, 2024 · strength 0.18
- Ho Kyoung Hwang · 1 shared paper, 2024 · strength 0.18
- Chang Moo Kang · 1 shared paper, 2024 · strength 0.18
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.